STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNMD
  4. [Form 4] CONMED Corp Insider Trading Activity

Director Mark Kaye receives 5,772 RSUs at CONMED (NYSE: CNMD)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CONMED Corp director Mark Kaye reported equity compensation activity, not open-market trading. He received an award of 5,772 restricted stock units (RSUs), each representing a contingent right to one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year.

On a separate line, 668 RSUs were converted into 668 shares of common stock at a stated price of $0.00 per share, reflecting the non-cash nature of this compensation. Following this exercise, Kaye directly holds 820 shares of common stock and retains 5,772 unvested RSUs scheduled to vest after their one-year period, subject to plan terms.

Positive

  • None.

Negative

  • None.
Insider Kaye Mark
Role null
Type Security Shares Price Value
Exercise RSUs (Restricted Stock Units) 668 $0.00 --
Exercise Common Stock 668 $0.00 --
Grant/Award RSUs (Restricted Stock Units) 5,772 $0.00 --
Holdings After Transaction: RSUs (Restricted Stock Units) — 0 shares (Direct, null); Common Stock — 820 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
New RSU grant 5,772 RSUs Grant reported as of June 1, 2026 under 2025 Long-Term Incentive Plan
RSUs exercised 668 RSUs Converted into 668 common shares on June 2, 2026
Exercise price $0.00 per share Stated for RSU exercise into common stock
Common shares held after 820 shares Direct ownership following RSU exercise on June 2, 2026
RSU vesting schedule 100% after one year Applies to RSUs under 2025 Long-Term Incentive Plan
RSU expiration date (grant) June 1, 2036 Expiration for 5,772 RSUs granted as of June 1, 2026
RSU expiration date (exercised lot) June 2, 2035 Original expiration for 668 RSUs that were exercised
Restricted Stock Unit (RSU) financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
2025 Long-Term Incentive Plan financial
"will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan"
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kaye Mark
(Last)(First)(Middle)
C/O CONMED CORPORATION
11311 CONCEPT BOULEVARD
(Street)
LARGO FLORIDA 33773
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/02/2026M668A$0820D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
RSUs (Restricted Stock Units)$006/01/2026A5,77206/01/2027(1)06/01/2036Common Stock5,772$05,772D
RSUs (Restricted Stock Units)$006/02/2026M66806/02/2026(2)06/02/2035Common Stock668$00D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
/s/ Thomas Fistek for Mark Kaye by Power of Attorney06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CONMED (CNMD) director Mark Kaye report?

Mark Kaye reported equity compensation, not open-market trades. He exercised 668 RSUs into 668 CONMED common shares and received a new grant of 5,772 RSUs. These awards are part of his compensation rather than discretionary stock purchases or sales.

How many RSUs did CONMED (CNMD) grant to director Mark Kaye?

CONMED granted Mark Kaye 5,772 RSUs. Each restricted stock unit represents a contingent right to receive one share of common stock, generally vesting 100% after one year under the company’s 2025 Long-Term Incentive Plan and subject to its terms and conditions.

Did Mark Kaye buy or sell CONMED (CNMD) shares on the open market?

The filing shows no open-market buys or sells. Reported transactions reflect an RSU grant and the exercise of 668 RSUs into common stock at $0.00 per share, indicating routine equity compensation activity rather than discretionary trading in CONMED shares.

What are the vesting terms of Mark Kaye’s new CONMED (CNMD) RSUs?

The 5,772 RSUs generally vest 100% after one year. Each unit converts into one share of CONMED common stock, subject to the terms and conditions of the company’s 2025 Long-Term Incentive Plan, which governs eligibility, vesting, and other award provisions.

How many CONMED (CNMD) common shares does Mark Kaye hold after these transactions?

After the RSU exercise, Mark Kaye directly holds 820 common shares. This comes from converting 668 RSUs into common stock, as reported in the non-derivative table. He also retains 5,772 unvested RSUs that may settle in additional shares upon vesting.

What is the nature of the RSU exercise reported by CONMED (CNMD) director Mark Kaye?

The RSU exercise is a non-cash derivative conversion. 668 RSUs were converted into 668 CONMED common shares at a stated price of $0.00 per share, consistent with equity awards settling into stock rather than an open-market purchase at prevailing trading prices.